Boundless Bio, Inc.
BOLD
$1.50
-$0.03-1.96%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 4.96M | 4.63M | 4.66M | 3.75M | 3.38M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 18.28M | 18.72M | 19.39M | 16.88M | 13.80M |
Operating Income | -18.28M | -18.72M | -19.39M | -16.88M | -13.80M |
Income Before Tax | -16.45M | -16.51M | -16.98M | -15.43M | -12.14M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -16.45M | -16.51M | -16.98M | -15.43M | -12.14M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -16.45M | -16.51M | -16.98M | -15.43M | -12.14M |
EBIT | -18.28M | -18.72M | -19.39M | -16.88M | -13.80M |
EBITDA | -17.98M | -18.45M | -19.13M | -16.62M | -13.55M |
EPS Basic | -0.74 | -0.74 | -0.77 | -12.27 | -9.77 |
Normalized Basic EPS | -0.46 | -0.46 | -0.48 | -7.67 | -6.11 |
EPS Diluted | -0.74 | -0.74 | -0.77 | -12.27 | -9.77 |
Normalized Diluted EPS | -0.46 | -0.46 | -0.48 | -7.67 | -6.11 |
Average Basic Shares Outstanding | 22.28M | 22.25M | 22.02M | 1.26M | 1.24M |
Average Diluted Shares Outstanding | 22.28M | 22.25M | 22.02M | 1.26M | 1.24M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |